Kohei Shitara, MD

Articles by Kohei Shitara, MD

1 expert is featured in this series

Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study

ByKohei Shitara, MD

November 11th 2026

Rapid readout: Phase 3 GHOPE-001 shows claudin 18.2 ADC AT extends PFS/OS vs chemo in late-line gastric/GEJ cancer, manageable safety.

Latest Updated Articles

Trending on OncLive

FDA Approves Pimicotinib for Symptomatic TGCT

Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis

Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer

Dr Natsuhara on Treatment Advances and Research Considerations in TNBC

NATALEE 6-Year OS Data and Novel ADCs in Breast Cancer Take Center Stage at ESMO 2026